Evidence map›Paper›PMID 41071392›Full record

ReviewBrain tumor pathology2026

Primary sellar glomus tumor with BRAF K601E mutation: an aggressive tumor of uncertain malignant potential.

Bin Mi, Benjamin Ka Seng Thong, Li Jiang, Xue Wang

Abstract readCase ReportsReview
PubMed Publisher
In one paragraph

Review in Brain tumor pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Bin Mi *Department of Pathology, Pingyi County People's Hospital, Linyi, China.
Benjamin Ka Seng Thong *Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Li JiangDepartment of Pathology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. bzjiangli@163.com.
Xue WangDepartment of Pathology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. wx12460@rjh.com.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glomus tumor (GT) is a mesenchymal neoplasm composed of modified perivascular cells exhibiting smooth muscle-like features, resembling those of the normal glomus body. The lesions often occur in areas rich in glomus vascularis, most of which occur in the distal limbs, while the sellar GT is extremely rare. Here, we present a case of primary sellar GT harboring a BRAF K601E mutation, identified through next-generation sequencing. The patient has been followed for 10 years, with tumor recurrence noted in the fourth year post-surgery. This report highlights the histological features, biological behavior, clinical manifestations, and prognosis of sellar GTs with a BRAF K601E mutation. Literature review suggests that determining the biological behavior of sellar GTs remains challenging, complicating diagnosis and treatment planning. We summarize the clinical and pathological characteristics of sellar GTs and propose considerations for pathological diagnosis based on our findings.

Indexed as

Glomus TumorMutationPituitary NeoplasmsProto-Oncogene Proteins B-rafFemaleHumansMaleNeoplasm Recurrence, LocalBRAF protein, humanProto-Oncogene Proteins B-rafBRAF K601E mutationGlomus tumorGlomus tumor of uncertain malignant potentialMalignant glomus tumorSellar region

Identifiers

PMID41071392

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.